Government regulators said Friday the connection between Pfizer’s anti-smoking drug Chantix and serious psychiatric problems is “increasingly likely.”

Government regulators said Friday the connection between Pfizer’s anti-smoking drug Chantix and serious psychiatric problems is “increasingly likely.” The Food and Drug Administration began in November investigating reports of depression, agitation and suicidal behavior in patients taking the popular twice-daily pill.

The agency’s announcement comes two weeks after Pfizer added stronger warnings to the drug. In doing so, the company stressed that a direct link between Chantix and the reported psychiatric problems has not been established, but could not be ruled out.  Since most anti-smoking drugs are typically used as anti-depressants this should come as no surpise to anyone.

This entry was posted on Sunday, February 3rd, 2008 at 11:19 am and is filed under Medical Discorveries, Health Info, Breaking Health News, General Health. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.